CFD Therapeutics

CFD Therapeutics is a preclinical-stage biotechnology company dedicated to discovering and developing next-generation small molecule inhibitors of the complement system. The company specifically targets Complement Factor D (CFD), a rate-limiting enzyme in the alternative pathway of the complement cascade. Their primary therapeutic focus includes complement-mediated diseases such as geographic atrophy (GA) and paroxysmal nocturnal hemoglobinuria (PNH). By leveraging deep expertise in medicinal chemistry and complement biology, the company is engineering highly potent and selective molecules for both oral and local administration. CFD Therapeutics was founded by industry veterans with a proven track record in complement drug discovery and development.